Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Cash & Equivalents (2018 - 2025)

TransMedics (TMDX) has 8 years of Cash & Equivalents data on record, last reported at $488.4 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 45.07% year-over-year to $488.4 million; the TTM value through Dec 2025 reached $488.4 million, up 45.07%, while the annual FY2025 figure was $488.4 million, 45.07% up from the prior year.
  • Cash & Equivalents reached $488.4 million in Q4 2025 per TMDX's latest filing, up from $466.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $488.4 million in Q4 2025 and bottomed at $22.5 million in Q3 2021.
  • Average Cash & Equivalents over 5 years is $272.7 million, with a median of $333.4 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: tumbled 50.51% in 2021, then skyrocketed 686.48% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $25.6 million in 2021, then surged by 686.48% to $201.2 million in 2022, then surged by 96.25% to $394.8 million in 2023, then fell by 14.73% to $336.6 million in 2024, then skyrocketed by 45.07% to $488.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $488.4 million in Q4 2025, $466.2 million in Q3 2025, and $400.6 million in Q2 2025.